Sun Pharma Announces Q4 and Full Year Results for FY26, Highlights 13.6% Q4 Sales Growth

Sun Pharma Announces Q4 and Full Year Results for FY26, Highlights 13.6% Q4 Sales Growth​

Mumbai, May 22, 2026 – Sun Pharmaceutical Industries Limited today announced its consolidated financial results for the fourth quarter ending March 31, 2026, and the full financial year 2026. The results reflect continued growth, with the company reporting sales of Rs. 145,598 million in Q4FY26, marking a 13.6% year-over-year increase.

The company's full-year performance for FY26 saw total sales reach Rs. 582,201 million, representing an 11.9% growth compared to the previous year. Net profit after tax (PAT) was recorded at Rs. 114,794 million, achieving a 5.0% increase year-over-year.

Innovative Medicines Drive Growth​

A key growth driver was the Innovative Medicines segment. Global Innovative Medicines sales reached US$ 354 million in Q4FY26, a 20.1% increase year-over-year. For the full year FY26, these sales amounted to US$ 1,420 million, demonstrating a 16.8% growth (excluding milestones).

EBITDA for the fourth quarter stood at Rs. 39,542 million, up 6.4% year-over-year, with the quarterly EBITDA margin recorded at 27.1%. Over the full financial year, EBITDA reached Rs. 177,314 million, up 16.1%, achieving an EBITDA margin of 30.3%.

Segment Performance Highlights​

The company’s overall Indian Formulations segment generated sales of Rs. 48,358.9 million in Q4FY26, registering a growth of 14.8%. For the full year, India Formulations contributed Rs. 192,903.6 million, growing 14% and accounting for 33.2% of total consolidated sales.

In the US market, total formulations sales reached US$ 459 million in Q4FY26. Over the full year FY26, US Formulations generated US$ 1,904 million. Emerging Markets (EM) Formulations sales were US$ 306 million in Q4FY26, up 17.4%, and totaled US$ 1,265 million for the full year, forming 19.2% of total consolidated sales.

Dividend and Market Position​

The Board of Directors, taking note of the strong performance, proposed a final dividend of Rs. 5.00 per equity share for FY26. This amount, combined with the interim dividend of Rs. 11.00 per share paid in FY26, brings the total dividend for the fiscal year to Rs. 16.00 per share, mirroring the payout from FY25.

The Managing Director noted that the company's full-year performance reflects significant achievements, citing the India market share gain of 0.3 percentage points as the highest gain since the Ranbaxy acquisition.

The following table summarizes the key financial highlights for the quarter and the full year:


The company’s comprehensive portfolio includes an active R&D pipeline. The pipeline features candidates such as Ilumya, which is currently eligible for a PDUFA Date in October-26, and Fibromun, which is in Phase 2 for soft tissue sarcoma and glioblastoma indications.

***
(The detailed financial results and divisional breakdowns are available in the accompanying presentation materials.)

SUNPHARMA Stock Price Movement​

As of 3:26 PM, shares of Sun Pharmaceutical Industries Limited are shedding 2.75% in live trading, currently priced at ₹1839.3. The stock has shed ₹52.00 today, drawing 2.73 million shares in volume and noting its recent peak near its 52-week high of ₹1916.6.